Nathan Becker
Endocrinology, Diabetes & Metabolism · San Francisco, CANPI 1972696250
Payments from drug & device makers
Across 216 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$709
- IBSA Pharma Inc.$661
- AbbVie$577
- AstraZeneca$278
- Amgen$125
- plus $120 from 3 others
What the payments were for
- Food & beverage$3,77899%
- Education$441%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 67 | $1,351 |
| Novo Nordisk | 70 | $709 |
| IBSA Pharma Inc. | 30 | $661 |
| AbbVie | 34 | $577 |
| AstraZeneca | 7 | $278 |
| Amgen | 1 | $125 |
| Boehringer Ingelheim | 4 | $67 |
| Radius Health, Inc. | 2 | $31 |
| Vertical Pharmaceuticals, LLC | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,822 in reported general payments places this provider in the 60th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 118 | $155,791 |
| SynthroidLevothyroxine Sodium | 931 | $91,065 |
| ForteoTeriparatide | 18 | $75,758 |
| TirosintLevothyroxine Sodium | 251 | $57,476 |
| JardianceEmpagliflozin | 52 | $57,123 |
| Liothyronine Sodium | 773 | $45,417 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 34 | $39,491 |
| OzempicSemaglutide | 26 | $33,076 |
| JanuviaSitagliptin Phosphate | 30 | $22,914 |
| Tirosint-SolLevothyroxine Sodium | 88 | $22,347 |
| Estradiol | 60 | $8,222 |
| VascepaIcosapent Ethyl | 19 | $6,929 |
| EliquisApixaban | 12 | $6,795 |
| Vivelle-DotEstradiol | 18 | $6,023 |
| DottiEstradiol | 39 | $5,483 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $709 | $188,867144 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $67 | $96,61486 claims |
| AbbVieSynthroid | $577 | $91,065931 claims |
| IBSA Pharma Inc.Tirosint, Tirosint-Sol | $661 | $79,823339 claims |
| Lilly USA, LLCForteo | $1,351 | $75,75818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in San Francisco
- Marc HellersteinSan Francisco$1.2M
- Edward HsiaoSan Francisco$766K
- Cheng Yang TuanSan Francisco$568K
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.